ESPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Esperion Therapeutics Inc (ESPR) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown significant revenue growth, its declining net income and EPS, coupled with insider selling, neutral hedge fund sentiment, and lack of strong technical or trading signals, make it a less compelling investment at this time.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 42.419, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level of 2.429, with resistance at 3.105.
Gross margin improved to 83.46%, up 32.67% YoY. Analysts have raised the price target to $5 with an Outperform rating.
Net income dropped by -390.04% YoY, and EPS fell by -336.36% YoY. Insiders are selling heavily, with a 2002.57% increase in selling activity over the last month. No recent news or congress trading data to provide additional confidence.
In Q4 2025, revenue increased significantly to $168.45 million, but net income dropped to $61.83 million, and EPS declined to 0.26. Gross margin improved to 83.46%.
Analysts are positive, with Citizens raising the price target to $5 and maintaining an Outperform rating, citing pipeline expansion and strategic acquisitions.
